



Matthew-Wood syndrome is caused by truncating mutations in the retinol-binding protein receptor gene STRA6.

Christelle Golzio, Jelena Martinovic-Bouriel, Sophie Thomas, Soumaya Mougou-Zrelli, Bettina Grattagliano-Bessieres, Maryse Bonniere, Sophie Delahaye, Arnold Munnich, Ferechte Encha-Razavi, Stanislas Lyonnet, et al.

► To cite this version:

Christelle Golzio, Jelena Martinovic-Bouriel, Sophie Thomas, Soumaya Mougou-Zrelli, Bettina Grattagliano-Bessieres, et al.. Matthew-Wood syndrome is caused by truncating mutations in the retinol-binding protein receptor gene STRA6.. American Journal of Human Genetics, 2007, 80 (6), pp.1179-87. 10.1086/518177 . hal-00172593

HAL Id: hal-00172593

<https://hal.science/hal-00172593>

Submitted on 17 Sep 2007

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Matthew-Wood syndrome is caused by truncating mutations in the retinol binding protein receptor gene *STRA6*

Christelle Golzio^{1,5}, Jelena Martinovic-Bouriel², Sophie Thomas¹, Soumaya Mougou-Zrelli², Bettina Grattagliano-Bessi res³, Maryse Bonni re², Sophie Delahaye^{4,5}, Arnold Munnich^{1,2,5}, F rech t  Encha-Razavi^{1,2,5}, Stanislas Lyonnet^{1,2,5}, Michel Vekemans^{1,2,5}, Tania Atti -Bitach^{1,2,5}, Heather C. Etchevers^{1,6}

Running title: *STRA6* mutations in Matthew-Wood syndrome

¹ INSERM U781, H pital Necker – Enfants Malades, Paris, France

² Assistance Publique – H pitaux de Paris; H pital Necker – Enfants Malades, Dept. of Genetics, 149 rue de S vres, Paris, France

³ Institut de Pu riculture, Dept. of Fetal Pathology, 26 boulevard Brune, Paris, France

⁴ Assistance Publique – H pitaux de Paris, H pital Necker – Enfants Malades, Dept. of Obstetrics, 149 rue de S vres, Paris, France

⁵ Universit  Ren  Descartes-Paris 5, H pital Necker – Enfants Malades, France

⁶ INSERM U563, H pital Purpan, Toulouse, France

Corresponding Author : Dr. Heather C. Etchevers, INSERM U781, H pital Necker, 149 rue de S vres, 75743 Paris Cedex 15, France Tel. : +33 1 44 49 56 11; Fax : +33 1 44 49 51 50;
Email : etchevers@necker.fr

Keywords : STRA6, retinoic acid, microphthalmia, diaphragmatic hernia, cardiopathy, pulmonary, congenital, embryo

Abstract

Retinoic acid (RA) is a potent teratogen in all vertebrates when tight homeostatic controls on its endogenous dose, location or timing are perturbed during early embryogenesis. *STRA6* encodes an integral cell membrane protein that favors RA uptake from soluble retinol-binding protein; its transcription is directly regulated by RA levels. Molecular analysis of *STRA6* was undertaken in two consanguineous human fetuses we previously described with the Matthew-Wood syndrome [MIM 601186] in a context of severe microphthalmia, pulmonary agenesis, bilateral diaphragmatic eventration, duodenal stenosis, pancreatic malformations and intrauterine growth retardation. The fetuses had either a homozygous insertion/deletion in exon 2 or a homozygous insertion in exon 7, respectively, predicting a premature stop codon in *STRA6* transcripts. Five other fetuses presenting at least one of the two major signs of clinical anophthalmia or pulmonary hypoplasia with at least one of the two associated signs of diaphragmatic closure defect or cardiopathy had no *STRA6* mutations. These findings suggest a molecular basis for the prenatal manifestations of Matthew-Wood syndrome and that phenotypic overlap with other associations may be due to genetic heterogeneity of elements common to the RA and fibroblast growth factor signaling cascades.

Microphthalmia refers to a clinical spectrum that is characterized by a congenital reduction in the size of the optic globe(s), which may be reduced to a vestige only visible on histological analysis. This most severe form of microphthalmia is sometimes called secondary or clinical anophthalmia, and occurs later in development than primary anophthalmia, due to a lack of optic vesicle formation from the embryonic prosencephalon. Isolated severe microphthalmia/anophthalmia demonstrates both genetic and phenotypic heterogeneity in humans, currently implicating genes coding for transcription factors. *CHX10* mutations lead to microphthalmia, coloboma and cataracts ^{1,2}; mutations in the *RAX* gene have been identified in an individual with unilateral anophthalmia and sclerocornea in the other eye ³. *PAX6* mutations lead to diverse congenital ocular malformations, the most common of which is aniridia, but a few genotypes have been described to date that engender primary anophthalmia ⁴ or microphthalmia ⁵⁻⁷, as documented in the *PAX6* Allelic Variant Database.

Syndromic microphthalmias can be associated with craniofacial dysmorphic features, heart and vascular malformations, skeletal and limb anomalies, skin or gut defects, mental retardation and hydrocephalus or combinations thereof [MIM 164180, 206900, 206920, 248450, 300166, 301590, 309801, 600776, 605856, 607932, 610125, 610126, 601349]. Although rare, the association of severe microphthalmia and pulmonary hypoplasia [MIM 601186] is a distinct entity known as Matthew-Wood syndrome ⁸. Most authors have reported further associations of MWS with cardiac and/or diaphragmatic malformations and intrauterine growth retardation (IUGR) ⁹⁻¹³.

We have excluded mutations in genes encoding the fibroblast growth factor *FGF10* and its receptor *FGFR2IIIb* respectively in two familial cases of MWS ¹⁴. These proteins are essential for the development of all affected organs in MWS ¹⁵⁻¹⁷. Meanwhile, *STRA6* gene

mutations were recently implicated in heterogeneous postnatal associations of clinical anophthalmia, pulmonary hypoplasia, diaphragmatic hernia, and cardiac defects¹⁸. A molecular analysis of the *STRA6* gene was undertaken in the two MWS families we had described as well as in five other fetuses presenting at least one of the two major signs of clinical anophthalmia or pulmonary hypoplasia and at least one of the two associated signs of diaphragmatic closure defect or cardiopathy.

In all seven fetuses examined, the presence of severe malformations was noted on ultrasound examination and after genetic counseling, pregnancies were interrupted. Clinical data are summarized in Table 1. Chromosome and molecular analyses and pathological examinations were carried out in all cases with full parental consent. Genomic DNA was extracted from frozen tissue in fetal cases and from peripheral blood samples for parents according to standard protocols.

Polymorphic markers D15S188, D15S160, D15S991, D15S114, flanking the *STRA6* gene, were chosen using the UCSC Genome Browser and examined in fetal cases 1 and 2 (Figure 1). The parents of case 1 are a consanguineous couple of Romanian origin, and the parents of case 2 are a consanguineous couple of Portuguese origin¹⁴. Homozygous haplotypes were demonstrated in each fetus, while the clinically unaffected parents of case 1 had a heterozygous haplotype with an allele presumably inherited from a common ancestor (DNA was unavailable from the other family members of case 2).

Primers were subsequently designed to cover the 20 exons and exon-intron junctions of the *STRA6* gene (NM_022369), including exon 1A and 1B (the first non-coding exon may be alternatively spliced), using Primer3 software¹⁹ (Table 2). PCR reactions were treated with the ExoSAP enzyme mix as per manufacturer's instructions (GE-Amersham). Sequencing was

performed for all seven fetal DNAs using Big Dye v3.1 Terminator Cycle Sequencing Reactions on an ABI 3130 (Applied Biosystems). Both the sense and antisense strands of the PCR-amplified fragments were analyzed with Sequence Analysis software (Applied Biosystems).

Cases 1 and 2 both presented homozygous mutations in the coding sequence of *STRA6* (Figure 1). A homozygous insertion/deletion in exon 2 (c.50_52delACTinsCC) for fetus 1 causes a frameshift and the appearance of a premature stop codon (p.Asp17Ala fsX55). An older brother with isolated bilateral coloboma of the retina and iris was heterozygous for this mutation, as were the clinically unaffected parents. Case 2 presented a homozygous single base insertion in exon 7 (c.527_528insG) that also predicts a premature stop codon (p.Gly176Gly fsX59).

Case 4 had six intronic variations and one conservative amino acid substitution (Table 3), all of which were homozygous and documented single nucleotide polymorphisms in the general population (dbSNP). Parental samples for fetus 4 were not available for analysis. As the fetus was not known to come from a consanguineous background and had a normal karyotype, the hypothesis of a small, heterozygous deletion was considered. QMPSF (quantitative multiplex PCR of small fluorescent fragments)²⁰, was undertaken to measure the number of genomic *STRA6* copies for case 4. The results indicated that this fetus did not present a deletion of the *STRA6* gene that would explain the observed homozygosity of the SNPs (data not shown).

A single heterozygous variation located in intron 13 (c.1407+32G>A) was observed in case 5, that has not been identified to date in dbSNP (Table 3). We screened 260 control chromosomes without observing the c.1407+32G>A variation. The only tissue available from

fetus 5 for expression analysis was a frozen lung sample. *STRA6* transcripts were not observed in either total lung RNA extracted from an age-matched fetus affected with an unrelated disorder or from the case 5 tissue sample (data not shown). Therefore, the consequence of this variation on *STRA6* transcription remains to be determined.

We report homozygous mutations in the *STRA6* gene in two fetuses presenting the principal features of MWS, including bilateral severe microphthalmia and pulmonary agenesis. Both also had bilateral diaphragmatic eventration and one had a cardiac malformation. The observation that both fetuses came from consanguineous families and, moreover, that one family demonstrated sibling recurrence, had already evoked a recessive model of inheritance for MWS¹⁴. By finding the molecular anomaly, it is now possible to affirm that MWS is indeed an autosomal recessive disorder that can be ascribed to mutations in the *STRA6* gene.

These two *STRA6*-mutated fetuses would not have survived postnatally. In both cases, the mutations would have led to a truncated protein if translated. Homozygous *STRA6* mutations have also been observed in peri- and postnatal patients from two other families as well as in three sporadic cases with a similar phenotypic spectrum¹⁸. However, four missense mutations were found to be associated with a severe clinical phenotype while two cases with a truncating mutation had milder clinical signs, with no growth retardation or apparent pulmonary anomalies. Indeed, one of those patients has survived into his teens. Comparison of all reported patients with *STRA6* mutations (Table 1) thus demonstrates that there is no correlation to date between the nature of a coding mutation and the severity of the phenotype.

The recent functional study of fifty random missense mutations introduced into bovine *Stra6* has shown that a few of these are sufficient to prevent cell surface expression and one, although allowing protein insertion into the membrane, abrogates vitamin A entry into the cell

²¹. Similar studies will now need to be conducted with documented human mutations in order to draw conclusions, but it is probable that phenotypic severity is a result of the reduction in perceived retinoic acid (RA) dose within sensitive target tissues, rather than a simple distinction between missense and nonsense mutations.

We also undertook molecular analysis of *STRA6* in five other fetuses with pulmonary and ocular or cardiac malformations, but no other patent mutations were identified, despite some intriguing variations (Table 3). The clinical diversity of patients with *STRA6* mutations, and the large phenotypic overlap with those who are not mutated, strongly suggests that MWS and related syndromes are not only clinically but genetically heterogeneous.

The only necessary diagnostic criterion predicting the involvement of *STRA6*, based on the patients currently reported here and in the previous study ¹⁸, is severe microphthalmia (clinical anophthalmia). Microphthalmia with any macroscopically residual presence of the ocular globe does not correlate with *STRA6* mutations in either series (Table 1). Obviously, since many genes have previously been identified in both isolated and syndromic microphthalmia, this feature is not sufficient to orient molecular testing. The severe eye malformations subsequent to *STRA6* mutations are always observed in association with at least one other sign, among those of pulmonary defects, congenital diaphragmatic eventration/hernia or cardiovascular malformation involving the common aortopulmonary trunk or pulmonary arteries. Furthermore, according to our two MWS cases and descriptions of MWS in the literature, pancreatic malformations and IUGR may also be secondary diagnostic criteria.

Pulmonary defects range from agenesis (this report) to hypoplasia or unilobar lung among mutated MWS families, to no obvious lung problems in either member of family 2 examined by Pasutto *et al.* ¹⁸. Pulmonary and diaphragmatic malformations

(eventration/hernia) are not always associated, occurring separately or in combination even among members of the same family¹⁸. This observation leads us to conclude that in the context of *STRA6* mutations, the pulmonary phenotype of mutated patients is a primary malformation and not a consequence of diaphragmatic hernia. However, the joint presence of clinical anophthalmia and pulmonary and/or diaphragmatic anomalies is still not sufficient to guarantee *STRA6* involvement, because other cases with bilateral anophthalmia and hypoplastic lungs (MWS patients GM23728 and CD50396 from Pasutto *et al.*¹⁸ and our case 4) do not present coding sequence mutations (Table 1).

Cardiovascular involvement is frequent, but inconstant. Case 2 had a ventricular septal defect and pulmonary trunk agenesis, while case 1 presented isolated agenesis of the pulmonary arteries. Furthermore, *STRA6* mutations described by Pasutto *et al.* also give rise to conotruncal or great artery malformations (truncus arteriosus, tetralogy of Fallot, pulmonary valve or arterial stenosis, right aortic arch) in at least some family members¹⁸. Other affected members with identical mutations had no cardiovascular signs (cf. MWS4-BE). Previously described cases of MWS^{9, 12} also show a preponderance of pulmonary artery absence, ductus arteriosus or ventricular septal defects.

Fryns syndrome [MIM 229850] has a clinical spectrum that includes diaphragmatic hernia and, less frequently, microphthalmia, facial dysmorphism and distal limb anomalies. Fetal case 3, presenting with bilateral microphthalmia, pulmonary hypoplasia, diaphragmatic hernia and cardiac involvement and cleft palate was diagnosed with Fryns syndrome. Despite the implication of the same organ systems as in MWS and absence of a digital phenotype, no mutations in the *STRA6* coding sequence were found. Patients GM23728 and CD50396 from Pasutto *et al.*¹⁸ also had a similar phenotype (Table 1); the latter was diagnosed with MWS,

presented true clinical anophthalmia and had a cleft palate. Palate involvement might therefore be suggestive of Fryns syndrome rather than MWS. Phenotypic overlap between these two disorders indicates that similar cases diagnosed with Fryns or MWS have either a non-coding mutation in *STRA6* or involve another gene necessary for the cellular interpretation of RA levels. For some authors, animal models of retinoid deficiency also evoke the PAGOD syndrome [MIM 202660] (pulmonary tract and pulmonary artery, agnathism, omphalocele, diaphragmatic defect, and dextrocardia) which shares features with Fryns and MWS ²².

RA, a small lipophilic hormone derived from retinol (vitamin A), is a ligand for nuclear receptors ($RAR\alpha$, β and γ), that act in homodimers or in heterodimers with RXR partners to bind DNA and regulate the expression of many genes, including the *Stra* (stimulated by retinoic acid) targets ^{23,24}. The functionally identified *Stra* genes have different roles and structurally unrelated products. For example, *Stra1* encodes ephrin B1, a bidirectional, membrane-bound signalling molecule highly expressed in the embryonic neural crest ²⁵; *Stra7*, later identified as the evolutionarily conserved transcription factor Gbx2 ²⁶, partners with the homeobox transcription factor *Otx2* in the specification of the isthmus organizer (midbrain/hindbrain junction) ²⁷.

Otx2 was also subsequently identified as a transcriptional target of RA, which leads to derepression of *Pax6* transcription in the optic cup ²⁸. Interestingly, both *OTX2* ²⁹ and *PAX6* ⁴ are responsible for human anophthalmias [MIM 610125 and MIM 607108.0005 respectively], through heterozygous loss-of-function with incomplete penetrance for the former and compound heterozygous loss-of-function engendering a primary anophthalmia for the latter. Mutations in *EFNB1* (encoding human ephrin B1) induce craniofrontonasal syndrome [MIM 304110], sometimes in association with congenital diaphragmatic hernia (CDH) ^{30,31}. We note

that *CRABP1* (cellular retinoic acid binding protein 1), another transcriptional target and effector of cytoplasmic RA levels ³², is located close to reported CDH loci in the long arm of chromosome 15. Experimental or teratogenic reductions in RA levels also lead to CDH in both animals and humans ^{33, 34}.

The murine *Stra6* gene encodes an integral transmembrane protein that is expressed in the developing eye, lung, other endodermal gut derivatives, limbs and somites ²³. In addition to being stimulated by RA, *Stra6* encodes a receptor for soluble retinol binding protein, efficiently mediating retinol uptake from the circulation into target cells ²¹.

Signaling by RA within the caudal pharyngeal endoderm of the vertebrate embryo is critical for the organization of the adjacent aortic arch vessels and heart. Sensitivity of only the most posterior aortic arches, which persist in direct continuity with the outflow tract of the heart, may be a result of the localized mesodermal production of retinaldehyde dehydrogenase 2 (*Raldh2*), a major enzyme for RA synthesis from retinol during development ³⁵. *Raldh2*^{-/-} mice demonstrate 3rd and 4th arch artery malformations with agenesis of the 6th arch ³⁶ in addition to cardiac septation defects ³⁷ and partial pancreatic agenesis ³⁸. The variable implication of the cardiac outflow tract and vascular derivatives of the embryonic 4th (definitive aorta) and 6th (ductus arteriosus and proximal pulmonary artery) aortic arches in our patients is consistent with an underlying field defect affecting the perception of RA dose by the endoderm.

Indeed, murine *Stra6* is highly expressed in the pharyngeal endoderm and mesenchyme along the embryonic gut ²³. Our two severely affected, mutated patients had duodenal stenosis and pancreatic malformations, in addition to lung agenesis. These organs are among the many

derivatives of the embryonic endoderm, produced by localized outpocketings into the mesoderm that will consolidate into the definitive structure.

RA is particularly necessary for normal growth and form of the lung. *Fgf10*^{-/-} mice demonstrate complete lung agenesis^{15, 16} while in knockout mice for the appropriate Fgf10-binding isoform of *Fgfr2*, the tracheal bifurcation at the origin of the bronchi is absent¹⁷. In *Raldh2*^{-/-} mouse embryos, *Fgf10* is no longer expressed in the lung bud and complete agenesis results³⁹. It appears likely that *Stra6*, expressed among other places in the *Raldh2*⁺ bronchial mesenchyme of the early lung²³, mediates retinol entry into the mesoderm and a subsequent effect on Fgfr2 signaling in the endoderm. Indeed, supplying exogenous RA for short periods can partially rescue both *Fgf10* expression and lung agenesis, leading to unilobar or unilateral right-sided lung development; longer rescue periods lead to better recovery and more subtle alveolar malformations⁴⁰.

Stra6 is also expressed at all stages of eye development, within the optic vesicle initially and later, within the periocular mesenchyme, the choroid and the optic nerve (and forebrain) meninges. Expression in the retinal pigment epithelium persists throughout adult life in both mouse and humans^{18, 23}, indicative of the continued need for RA for ocular function. The consistency of clinical anophthalmia in *STRA6*-mutated patients argues for the need for vitamin A uptake to further all stages of eye development following initial optic specification.

Stra6 transcripts are also detected in several other sites including the forebrain, the isthmus organizer and the neurohypophysis. However, no *STRA6*-mutated patients present central nervous system (CNS) malformations or pituitary anomalies, although IUGR or short stature may indicate a more subtle effect (Table 1). Murine expression patterns do not always suffice to explain clinical outcome⁴¹. Despite the strong, localized brain expression of the RA

target *Gbx2* (*Stra7*), its absence in mice gives rise only to posterior branchial arch anomalies and cardiac malformations, reminiscent of those observed in patients with *STRA6* mutations or in *Raldh2*^{-/-} mice⁴². There may also be species-specific differences in the RA sensitivity of the developing brain; the clinical spectrum of human vitamin A deficiency syndrome does not include the exencephaly observed in mouse models⁴³.

In conclusion, *STRA6* mutations are responsible for a large spectrum of congenital malformations with no current evidence of a genotype-phenotype correlation. Different transcriptional targets of RA signaling in humans appear to effect subset phenotypes of those observed in more generalized deficiencies⁴³. MWS is thus part of a growing family of human syndromes due to mutations in genes encoding effectors of the powerful developmental morphogen, retinoic acid.

Acknowledgements

The authors warmly thank Chantal Esculpavit, Annie Ebrac, Géraldine Goudefroye and Catherine Ozilou for their assistance and Jeanne Amiel and Patrick Calvas for critical discussion and reflection. Support has been provided by the National Institutes of Health (M.V, S.T.), the Association Française contre les Myopathies (H.E.) in addition to the Assistance Publique and the Institut National de la Santé et de la Recherche Médicale.

Web resources

PAX6 Allelic Variant Database, <http://pax6.hgu.mrc.ac.uk/>

Online Mendelian Inheritance in Man (OMIM), <http://www.ncbi.nlm.nih.gov/Omim/>

University of California Santa Cruz (UCSC) Genome Browser, <http://genome.ucsc.edu/cgi-bin/hgTracks> (reference sequence NM_022369)

Primer 3 software, http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi

Single Nucleotide Polymorphism Database, <http://www.ncbi.nlm.nih.gov/SNP/>

Mouse Genome Informatics, <http://www.informatics.jax.org>

References

1. Ferda Percin E, Ploder LA, Yu JJ, Arici K, Horsford DJ, Rutherford A, Bapat B, Cox DW, Duncan AM, Kalnins VI, et al. (2000) Human microphthalmia associated with mutations in the retinal homeobox gene CHX10. *Nat Genet* 25:397-401
2. Bar-Yosef U, Abuelaish I, Harel T, Hendler N, Ofir R, Birk OS (2004) CHX10 mutations cause non-syndromic microphthalmia/ anophthalmia in Arab and Jewish kindreds. *Hum Genet* 115:302-309
3. Voronina VA, Kozhemyakina EA, O'Kernick CM, Kahn ND, Wenger SL, Linberg JV, Schneider AS, Mathers PH (2004) Mutations in the human RAX homeobox gene in a patient with anophthalmia and sclerocornea. *Hum Mol Genet* 13:315-322
4. Glaser T, Jepeal L, Edwards JG, Young SR, Favor J, Maas RL (1994) PAX6 gene dosage effect in a family with congenital cataracts, aniridia, anophthalmia and central nervous system defects. *Nat Genet* 7:463-471
5. Azuma N, Yamaguchi Y, Handa H, Hayakawa M, Kanai A, Yamada M (1999) Missense mutation in the alternative splice region of the PAX6 gene in eye anomalies. *Am J Hum Genet* 65:656-663
6. Vincent MC, Pujo AL, Olivier D, Calvas P (2003) Screening for PAX6 gene mutations is consistent with haploinsufficiency as the main mechanism leading to various ocular defects. *Eur J Hum Genet* 11:163-169
7. Azuma N, Yamaguchi Y, Handa H, Tadokoro K, Asaka A, Kawase E, Yamada M (2003) Mutations of the PAX6 gene detected in patients with a variety of optic-nerve malformations. *Am J Hum Genet* 72:1565-1570

8. Li L, Wei J (2006) A newborn with anophthalmia and pulmonary hypoplasia (the Matthew-Wood syndrome). *Am J Med Genet A* 140:1564-1566
9. Berkenstadt M, Lev D, Achiron R, Rosner M, Barkai G (1999) Pulmonary agenesis, microphthalmia, and diaphragmatic defect (PMD): new syndrome or association? *Am J Med Genet* 86:6-8
10. Engellenner W, Kaplan C, Van de Vegte GL (1989) Pulmonary agenesis association with nonimmune hydrops. *Pediatr Pathol* 9:725-730
11. Seller MJ, Davis TB, Fear CN, Flinter FA, Ellis I, Gibson AG (1996) Two sibs with anophthalmia and pulmonary hypoplasia (the Matthew-Wood syndrome). *Am J Med Genet* 62:227-229
12. Spear GS, Yetur P, Beyerlein RA (1987) Bilateral pulmonary agenesis and microphthalmia. *Am J Med Genet Suppl* 3:379-382
13. Steiner RD, St JDP, Hopkin RJ, Kozielski R, Bove KE (2002) Combination of diaphragmatic eventration and microphthalmia/anophthalmia is probably nonrandom. *Am J Med Genet* 108:45-50
14. Martinovic-Bouriel J, Bernabe-Dupont C, Golzio C, Grattagliano-Bessieres B, Malan V, Bonniere M, Esculpavit C, Fallet-Bianco C, Mirlesse V, Le Bidois J, et al. (2007) Matthew-Wood syndrome: Report of two new cases supporting autosomal recessive inheritance and exclusion of FGF10 and FGFR2. *Am J Med Genet A* 143A:219-228
15. Min H, Danilenko DM, Scully SA, Bolon B, Ring BD, Tarpley JE, DeRose M, Simonet WS (1998) Fgf-10 is required for both limb and lung development and exhibits striking functional similarity to *Drosophila* branchless. *Genes Dev* 12:3156-3161

16. Sekine K, Ohuchi H, Fujiwara M, Yamasaki M, Yoshizawa T, Sato T, Yagishita N, Matsui D, Koga Y, Itoh N, et al. (1999) Fgf10 is essential for limb and lung formation. *Nat Genet* 21:138-141
17. De Moerlooze L, Spencer-Dene B, Revest J, Hajihosseini M, Rosewell I, Dickson C (2000) An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis. *Development* 127:483-492
18. Pasutto F, Sticht H, Hammersen G, Gillessen-Kaesbach G, FitzPatrick DR, Nürnberg G, Brasch F, Schirmer-Zimmermann H, Tolmie JL, Chitayat D, et al. (2007) Mutations in STRA6 Cause a Broad Spectrum of Malformations including Anophthalmia, Congenital Heart Defects, Diaphragmatic Hernia, Alveolar Capillary Dysplasia, Lung Hypoplasia, and Mental Retardation. *Am J Hum Genet* 80:550-560
19. Rozen S, Skaletsky H (2000) Primer3 on the WWW for general users and for biologist programmers. *Methods Mol Biol* 132:365-386
20. Saugier-veber P, Goldenberg A, Drouin-Garraud V, de La Rochebrochard C, Layet V, Drouot N, Le Meur N, Gilbert-Du-Ssardier B, Joly-Helas G, Moirrot H, et al. (2006) Simple detection of genomic microdeletions and microduplications using QMPSF in patients with idiopathic mental retardation. *Eur J Hum Genet* 14:1009-1017
21. Kawaguchi R, Yu J, Honda J, Hu J, Whitelegge J, Ping P, Wiita P, Bok D, Sun H (2007) A Membrane Receptor for Retinol Binding Protein Mediates Cellular Uptake of Vitamin A. *Science* 315:820-825

22. Macayran JF, Doroshow RW, Phillips J, Sinow RM, Furst BA, Smith LM, Lin HJ (2002)
PAGOD syndrome: eighth case and comparison to animal models of congenital
vitamin A deficiency. *Am J Med Genet* 108:229-234
23. Bouillet P, Sapin V, Chazaud C, Messaddeq N, Decimo D, Dolle P, Chambon P (1997)
Developmental expression pattern of *Stra6*, a retinoic acid-responsive gene encoding a
new type of membrane protein. *Mech Dev* 63:173-186
24. Bouillet P, Oulad-Abdelghani M, Vicaire S, Garnier JM, Schuhbaur B, Dolle P, Chambon
P (1995) Efficient cloning of cDNAs of retinoic acid-responsive genes in P19
embryonal carcinoma cells and characterization of a novel mouse gene, *Stra1* (mouse
LERK-2/Eplg2). *Dev Biol* 170:420-433
25. Davy A, Aubin J, Soriano P (2004) Ephrin-B1 forward and reverse signaling are required
during mouse development. *Genes Dev* 18:572-583
26. Bouillet P, Chazaud C, Oulad-Abdelghani M, Dolle P, Chambon P (1995) Sequence and
expression pattern of the *Stra7* (*Gbx-2*) homeobox-containing gene induced by retinoic
acid in P19 embryonal carcinoma cells. *Dev Dyn* 204:372-382
27. Hidalgo-Sanchez M, Millet S, Bloch-Gallego E, Alvarado-Mallart RM (2005)
Specification of the meso-isthmo-cerebellar region: the *Otx2/Gbx2* boundary. *Brain
Res Brain Res Rev* 49:134-149
28. Halilagic A, Ribes V, Ghyselinck NB, Zile MH, Dolle P, Studer M (2007) Retinoids
control anterior and dorsal properties in the developing forebrain. *Dev Biol* 303:362-
375
29. Ragge NK, Brown AG, Poloschek CM, Lorenz B, Henderson RA, Clarke MP, Russell-
Eggitt I, Fielder A, Gerrelli D, Martinez-Barbera JP, et al. (2005) Heterozygous

mutations of OTX2 cause severe ocular malformations. *Am J Hum Genet* 76:1008-1022

30. McGaughran J, Rees M, Battin M (2002) Craniofrontonasal syndrome and diaphragmatic hernia. *Am J Med Genet* 110:391-392
31. Vasudevan PC, Twigg SR, Mulliken JB, Cook JA, Quarrell OW, Wilkie AO (2006) Expanding the phenotype of craniofrontonasal syndrome: two unrelated boys with EFNB1 mutations and congenital diaphragmatic hernia. *Eur J Hum Genet* 14:884-887
32. Means AL, Thompson JR, Gudas LJ (2000) Transcriptional regulation of the cellular retinoic acid binding protein I gene in F9 teratocarcinoma cells. *Cell Growth Differ* 11:71-82
33. Clugston RD, Klattig J, Englert C, Clagett-Dame M, Martinovic J, Benachi A, Greer JJ (2006) Teratogen-induced, dietary and genetic models of congenital diaphragmatic hernia share a common mechanism of pathogenesis. *Am J Pathol* 169:1541-1549
34. Holder AM, Klaassens M, Tibboel D, de Klein A, Lee B, Scott DA (2007) Genetic Factors in Congenital Diaphragmatic Hernia. *Am J Hum Genet*: in press
35. Berggren K, McCaffery P, Drager U, Forehand CJ (1999) Differential distribution of retinoic acid synthesis in the chicken embryo as determined by immunolocalization of the retinoic acid synthetic enzyme, RALDH-2. *Dev Biol* 210:288-304
36. Niederreither K, Vermot J, Le Roux I, Schuhbaur B, Chambon P, Dolle P (2003) The regional pattern of retinoic acid synthesis by RALDH2 is essential for the development of posterior pharyngeal arches and the enteric nervous system. *Development* 130:2525-2534

37. Niederreither K, Vermot J, Messaddeq N, Schuhbaur B, Chambon P, Dolle P (2001)
Embryonic retinoic acid synthesis is essential for heart morphogenesis in the mouse.
Development 128:1019-1031
38. Martin M, Gallego-Llamas J, Ribes V, Kedinger M, Niederreither K, Chambon P, Dolle P,
Gradwohl G (2005) Dorsal pancreas agenesis in retinoic acid-deficient Raldh2 mutant
mice. Dev Biol 284:399-411
39. Desai TJ, Malpel S, Flentke GR, Smith SM, Cardoso WV (2004) Retinoic acid selectively
regulates Fgf10 expression and maintains cell identity in the prospective lung field of
the developing foregut. Dev Biol 273:402-415
40. Vermot J, Messaddeq N, Niederreither K, Dierich A, Dolle P (2006) Rescue of
morphogenetic defects and of retinoic acid signaling in retinaldehyde dehydrogenase 2
(Raldh2) mouse mutants by chimerism with wild-type cells. Differentiation 74:661-668
41. Fougereousse F, Bullen P, Herasse M, Lindsay S, Richard I, Wilson D, Suel L, Durand M,
Robson S, Abitbol M, et al. (2000) Human-mouse differences in the embryonic
expression patterns of developmental control genes and disease genes. Hum Mol Genet
9:165-173
42. Byrd NA, Meyers EN (2005) Loss of Gbx2 results in neural crest cell patterning and
pharyngeal arch artery defects in the mouse embryo. Dev Biol 284:233-245
43. Kastner P, Mark M, Chambon P (1995) Nonsteroid nuclear receptors: what are genetic
studies telling us about their role in real life? Cell 83:859-869

Cases	STR46 mutation	Eyes	Lungs	Diaphragm	Cardiovascular	Face	Other	Growth	Age at death	Consanguinity
Fetus 1*	p.D17A fsX55	bi AO	bi agenesis	bi eventr	bi absence of PA branches	mild dysmorphism	duodenal stenosis, annular pancreas	IUGR	31 wg	Yes, recurrence
Fetus 2*	p.G176G fsX59	bi AO	bi agenesis	bi eventr	pulmonary trunk and PA absence, VSD	mild dysmorphism	duodenal stenosis, absent pancreas, polylobed spleen	IUGR	28 wg	Yes
Fam2-IV:1	p.G50A fsX22	bi AO	-	CDH	ASD, VSD	mild dysmorphism	MR	SS	alive at 14 years	Yes, recurrence
Fam2-IV:3 (sib)	p.G50A fsX22	bi AO	n/a	CDH	n/a	mild dysmorphism	n/a	-	23 wg	
MWS4-BE	p.T644M	bi AO	hypo	CDH	-	-	bi hydronephrosis	-	alive at 3 months	No, recurrence
Brother MWS4-BE	n/a	n/a	hypo unilobar	-	Fallot, PDA	-	horseshoe kidney undescended testes	-	1 day	
Sister MWS4-BE	n/a	bi AO	hypo unilobar	-	PDA, CoA	-	uterine dysplasia	-	1 day	
MWS1-EE	p.R655C	bi AO	hypo	uni eventr	-	-	hypotonia uni inguinal hernia	-	3 months	Yes, recurrence
Brother MWS1-EE	n/a	bi AO	-	-	TA, RAA, PDA, PA atresia	-		SS	22 months	
MWS6-BK	p.P90L p.T321P	bi AO	hypo	CDH uni eventr	PDA	-	hypo kidneys bicornuate uterus	PTB (36 wg)	1 day	Yes, recurrence?
Fam1-IV:2	p.P293L	bi AO	ACD	-	PSt, PDA	mild dysmorphism	ectopic kidney DD	PTB (33 wg)	6 months	Yes, recurrence
Fam1-IV:4 (cousin)	n/a	bi AO	n/a	-	single ventricle PA atresia	n/a	-	-	2 days	
CD50396*	-	bi AO	hypo	uni eventr	VSD	CP hypo alae nasi	hypo bicornuate uterus hypo spleen	-	1 day	No
Fetus 3**	-	bi AO	hypo	bi CDH	hypo L ventricle and aorta, mitral valve atresia, VSD	CP	CC agenesis arhinencephaly Dandy-Walker	-	16 wg	No
Fetus 4	-	uni AO	-	-	single ventricle tricuspid valve atresia, ASD	-	arhinencephaly	-	22 wg	No
MWS3-KH	-	bi MO/AO	-	CDH	-	-	-	-	n/a	No

RHP006.070	-	bi MO/AO	-	bi eventr	-	-	MR	-	n/a	No
PB-E03_053	-	bi MO/AO	-	CDH	-	brachycephaly	MR, sparse hair bi inguinal hernia	-	alive at 10 years	No
GM23728	-	bi MO abnormal cornea, iris	-	hypo, uni eventr	hypo PA CoA	-	renal dysplasia	-	neonatal	No
AS20861-FE264	-	uni MO	-	CDH	-	-	ocular cyst, DD	-	alive at 13 months	No
MWS2-FA	-	bi coloboma	-	CDH	-	-	skin patches, brittle hair	-	n/a	Yes
MWS5-LR	-	coloboma	-	CDH	-	-	-	-	n/a	No
Fetus 5	-	-	-	hypo	dextroposed aorta over VSD	-	SUA	-	32 wg	No
AvdW22260	-	-	-	hypo	CDH	-	-	PTB (28 wg)	1 day	No
Twin 2 AvdW22260	-	-	-	hypo	CDH	CP	-	PTB (28 wg)	1 day	No
PM22479***	-	-	-	CDH	-	hypertelorism	hypo CC omphalocele	-	neonatal	Yes, recurrence
Brother*** PM22479	n/a	-	-	CDH	ASD	bi CLP hypertelorism	hypo CC	-	neonatal	
Fetus 6	-	-	-	bi hypo	L agenesis, R eventr	-	polysplenia renal dysplasia SUA	IUGR	30 wg	No
Fetus 7	-	-	-	bi agenesis	-	-	polysplenia renal agenesis	-	24 wg	No

Table 1. Overview of clinical features in cases undergoing *STR46* molecular analysis from our series (bold; fetuses 1-7) and Pasutto *et al.* 2007. * = diagnosed Matthew-Wood syndrome; ** = diagnosed Fryns syndrome; *** = suspected Donnai-Barrow syndrome. (*Abbr.* : ACD = alveolar capillary dysplasia; AO = clinical anophthalmia; ASD = atrial septal defect; bi = bilateral; CDH = congenital diaphragmatic hernia; CC = corpus callosum; CoA = coarctation of aorta; C(L)P = cleft (lip and) palate; DD = developmental delay; eventr = deventration; Fallot = tetralogy of Fallot; hypo = hypoplasia; IUGR = intrauterine growth retardation; L = left; MO = microphthalmia; MR = mental retardation; PA = pulmonary artery; PDA = persistent ductus arteriosus; PSt = pulmonary valve stenosis; PTB = preterm birth; R = right; RAA = right aortic arch; SS = postnatal short stature; SUA = single umbilical artery; TA = truncus arteriosus; uni = unilateral; VSD = ventricular septal defect; wg = weeks gestation).

Exon	Oligonucleotide sequences (5'→3')	
	Forward	Reverse
1a	GGGGTGGGTTCTCTGAT	CACCCCAGGTCTCCAAACT
1b	GCTGAAGGCAGGTATGTGTG	CCTCTCGTGTCCCCCTCCT
2	AAGCCTCTTTTCACATCTGTAGTG	CAGTTGCAACCTCTGCCATC
3	TGGGTAAAGCCTCAGTGTGA	GTTGGACTTGCATCCTGGTT
4	CAAGCCCTCAAACCTCAGACC	TGGGGGTCCTGACTAAACCT
5	CCACCTCCTTGATTTATGGAA	GCATCGTTGTAAAGACTGGATG
6-7	ACCTTCTCATTTTGCCCTTG	CTCAAAGGAGGCACTGTGGT
8	GCAACGGATTCTGGTTCTTG	GGAGTAGGGCTGTCTTGGG
9-10	ACGAATGGGTCGAGGCAG	TCTGTGCAAGGGAGGGTAAC
11	CTTGGGAGGGAGGAGGG	GGTTGAGGGCAGGGCTC
12	CCAGCGTCTCCCCTGTTAG	CATAGACCTTGGGTCTCCCC
13	TGGCAGGGGTCTTGAGG	CACAGGACTCCCACTCCTTC
14	TGGCCCAGAGGAGGATTTAG	CCAACTGAGGCCAGTGTCTG
15-16	AAAGCCCTTGGTTCTGGG	ACACCGAAGAAGAGGCGAG
17	AGGTCTGACACTGACCCTGG	GATGCCTTCCTCACTGCTTG
18	TGGATGCCTCCAGTGTGG	AGGGGCACACATCCTTCC
19	GATCAGGTCTGAGGGCCAG	GAGGAGGATGGTAGGCAGG

Table 2. *STR46* oligonucleotides used for sequencing. The annealing temperature for PCR was 60°C for all primers. For QMPSF, fluorescent primers corresponding to *STR46* exon 13 were used, and *MLH1* was chosen as a reference (GTAGTCTGTGATCTCCGTTT, 5'; ATGTATGAGGTCCTGTCCT, 3'). Co-amplification was carried out for 21 cycles, the peaks integrated and proportional DNA copy numbers estimated using Genotyper 3.7 software (Applied Biosystems).

Fetal case	Nucleotide changes versus NM_022369	Predicted effect on ORF	Known SNP reference	Status
1	c.50_52delACTinsCC	p.Asp17Ala fsX55		Homozygous
2	c.527_528insG	p.Gly176Gly fsX59		Homozygous
3	none			
4	c.331C>T	p.Leu111Leu	rs11857410	Homozygous
	c.406+97A>G		rs34147822	Homozygous
	c.406+111A>G		rs35255788	Homozygous
	c.430+24T>A		rs971756	Homozygous
	c.431-37C>T		rs971757	Homozygous
	c.1685-24T>C		rs12913041	Homozygous
	c.1840+50T>C		rs12912578	Homozygous
5	c.596+9T>G		rs28541560	Heterozygous
	c.1301-43A>C		rs351240	Heterozygous
	c.1416G>A	p.Ser472Ser	rs351241	Heterozygous
6	c.1166+32G>A			Heterozygous
7	c.1167-10C>G		rs2277608	Heterozygous

Table 3. Sequence variations in *STR46*.

Legend

Figure 1. Pedigrees of cases 1 and 2 with markers flanking the *STR46* gene and electropherograms. Case 1 (blue arrow) had a homozygous insertion/deletion in exon 2 of *STR46* (c.50_52delACTinsCC p.AspD17Ala fsX55). Case 2 (yellow arrow) had a homozygous insertion in exon 7 (c.527_528insG p.Gly176Gly fsX59). Markers D15S160, D15S991 and D15S114 were also homozygous; relatives' DNA is unavailable for further analysis. wg: weeks gestation

Figure 1.

